Overview

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2022-09-13
Target enrollment:
Participant gender:
Summary
Randomized single ascending dose placebo controlled treatment of ACH-000029 administered orally via capsule in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Syneos Health
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.